Telesis Bio (OTC: DNAY)
Telesis Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Telesis Bio Company Info
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Valuation
Earnings Transcripts
Codex DNA, Inc. (DNAY) Q2 2022 Earnings Call Transcript
DNAY earnings call for the period ending June 30, 2022.
Codex DNA, Inc. (DNAY) Q1 2022 Earnings Call Transcript
DNAY earnings call for the period ending March 31, 2022.
Codex DNA, Inc. (DNAY) Q4 2021 Earnings Call Transcript
DNAY earnings call for the period ending December 31, 2021.
Codex DNA, Inc. (DNAY) Q3 2021 Earnings Call Transcript
DNAY earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.